Supreme Court appears skeptical of LGBTQ conversion therapy bans
04:02
Iconic rainbow crosswalk removed in Miami Beach amid protests
02:13
Volunteers use chalk to restore crosswalk honoring Pulse shooting victims
02:32
Hate mail targets Ohio homes displaying Pride flags
01:36
NFL veteran hosts LGBTQ+ friendly football camp
02:42
'Let Them Stare' offers coming-of-age tale for a new generation
03:00
Two wounded when gunfire erupts near NYC Pride festivities
01:51
Pride Month concludes with fewer corporate sponsors amid DEI pushback
01:34
Supreme Court upholds Tennessee ban on youth gender-affirming care
05:27
Daniel Martin shares his journey as an Asian-American beauty industry trailblazer
03:45
Community angered over Washington's Dupont Circle Park closure during WorldPride
02:10
Nebraska becomes latest state to ban transgender students from girls sports
00:28
CEO behind HIV drug Truvada grilled on $3B in profits
Catch up with NBC News Clone on today's hot topic: Ceo Behind Hiv Drug Truvada Grilled On 3b In Profits 59819077674 - Breaking News | NBC News Clone. Our editorial team reformatted this story for clarity and speed.
02:23
Copied
Daniel O’Day, the chairman and CEO of Gliead Sciences Inc., is asked to explain U.S. pricing of HIV prevention drug Truvada for PrEP along with his company’s profits and his $30M signing bonus.May 17, 2019
